ImmunityBio announces public offering and $505M debt restructuring with Nant Capital

ImmunityBio, Inc.

Proposed public offering of common stock; Jefferies & Piper Sandler lead; 30-day option for 15% additional shares.
Contingent on offering, Nant Capital converts $230M notes into ~116.5M shares; remaining $505M note due 2027 at SOFR+8%.
Enters Limited Consent and Amendment to Revenue Interest Purchase Agreement with Oberland consenting to restructuring.
Shareholder derivative action filed Nov 20, 2024 in Delaware Chancery challenging Sept 2023 financing with Dr. Soon-Shiong.
Net proceeds to fund ANKTIVA commercialization, BCG-naïve NMIBC and NSCLC trials, and working capital.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.